SSC
STRO icon

Spruce Street Capital’s Sutro Biopharma STRO Stock Holding History

Spruce Street Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,594
Closed -$875K – 34
2025
Q4 		$875K Buy
+75,594
New +$717K 0.29% 27

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Spruce Street Capital's STRO Position: Q1 2026 in Review

Spruce Street Capital sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 75,594 shares — an estimated $875K sold.

Spruce Street Capital first reported a position in STRO in Q4 2025 and held it in 1 quarter. The position peaked at $875K in Q4 2025. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Spruce Street Capital reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • Spruce Street Capital sold 75,594 Sutro Biopharma shares in Q1 2026, an estimated $875K.
  • Spruce Street Capital first reported a position in Sutro Biopharma in Q4 2025 and held it in 1 quarter.
  • Spruce Street Capital's Sutro Biopharma position peaked at $875K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Spruce Street Capital's 13F filing for Q1 2026, filed 14 May 2026.